Wellington Management Group LLP Sells 236,586 Shares of Kyverna Therapeutics, Inc. $KYTX

Wellington Management Group LLP reduced its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 86.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 37,828 shares of the company’s stock after selling 236,586 shares during the period. Wellington Management Group LLP owned approximately 0.09% of Kyverna Therapeutics worth $73,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. raised its position in Kyverna Therapeutics by 2,225.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company’s stock valued at $1,728,000 after purchasing an additional 442,090 shares in the last quarter. Peapod Lane Capital LLC bought a new position in shares of Kyverna Therapeutics during the 1st quarter valued at about $765,000. Integral Health Asset Management LLC raised its holdings in shares of Kyverna Therapeutics by 75.0% during the 4th quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company’s stock valued at $1,309,000 after buying an additional 150,000 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Kyverna Therapeutics during the 4th quarter valued at about $299,000. Finally, Ameriprise Financial Inc. lifted its position in Kyverna Therapeutics by 55.1% in the 4th quarter. Ameriprise Financial Inc. now owns 190,383 shares of the company’s stock worth $712,000 after buying an additional 67,606 shares during the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KYTX has been the topic of a number of recent research reports. William Blair initiated coverage on shares of Kyverna Therapeutics in a research report on Wednesday, August 20th. They set an “outperform” rating on the stock. HC Wainwright increased their target price on shares of Kyverna Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.60.

Kyverna Therapeutics Stock Performance

NASDAQ:KYTX opened at $3.59 on Wednesday. Kyverna Therapeutics, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $8.28. The firm has a market cap of $155.27 million, a PE ratio of -0.98 and a beta of 3.08. The business has a 50 day moving average price of $3.55 and a 200-day moving average price of $2.84.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.03. Research analysts predict that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.